Intelligence · Patents
Patents expiring in 2034
Annual patent cliff calendar for 2034 — US pharmaceutical patents by expiration date.
- Patents
- 1,452
Quick answer
1,452 indexed pharmaceutical patents have expiration dates in 2034. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 8754201
Therapeutic compositions
granted -
US 8754124
Oligo-benzamide compounds and their use in treating cancers
granted -
US 8754081
Compositions and methods for inhibition of hepatocyte growth factor receptor c-Met signaling
granted -
US 8754050
Macrocyclic compounds useful as inhibitors of histone deacetylases
granted -
US 8754044
Neuroprotection by hepatic cells and hepatocyte secretory factors
granted -
US 8754034
Structure-based design of peptide inhibitors of amyloid fibrillation
granted -
US 8754051
Peptide modulators of the δPKC interaction with the d subunit of F1Fo ATP synthase/ATPase and uses thereof
granted -
US 8753682
Dual release oral tablet compositions of dexlansoprazole
granted -
US 8753660
Activating extraction of demineralized bone matrix
granted -
US 8754233
Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
granted -
US 8753646
IPV-DPT vaccine
granted -
US 8753649
Polysaccharide-protein conjugate vaccines
granted -
US 8754030
Defensin-antigen fusion proteins
granted -
US 8754046
MHC class II restricted T cell epitopes from the cancer anitgen, NY ESO-1
granted -
US 8754080
Pyrimidine substituted purine compounds as kinase (S) inhibitors
granted -
US 8754218
Salts of 6-heterocycle substituted hexahydrophenanthridine derivatives
granted -
US 8754224
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
granted -
US 8758813
Abuse-deterrent drug formulations
granted -
US 8759301
Gene fusion targeted therapy
granted -
US 8758311
Transdermal patch with extensor means
granted -
US 8759314
Methods for treating multiple sclerosis using antisense oligonucleotides
granted -
US 8759302
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
granted -
US 8758755
Stem cell fusion model of carcinogenesis
granted -
US 8758778
Polymeric nano-carriers with a linear dual response mechanism and uses thereof
granted -
US 8759332
Hepatitis C virus inhibitors
granted -
US 8759389
Thiophene-carboxamides useful as inhibitors of protein kinases
granted -
US 8759492
Engineered red-shifted channelrhodopsin variants
granted -
US 8759335
Modulators of ATP-binding cassette transporters
granted -
US 8759353
Co-crystals and pharmaceutical compositions comprising the same
granted -
US 8759325
Compositions and methods of treatment for inflammatory diseases
granted -
US 8759327
Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism
granted -
US 8759318
Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
granted -
US 8759340
Benzodiazepinone compounds useful in the treatment of skin conditions
granted -
US 8759296
Bone morphogenic protein binding peptide
granted -
US 8759014
Methods of obtaining antigen-specific T cell populations
granted -
US 8758817
Dosage form containing (S)-pantoprazole as active ingredient
granted -
US 8759006
PSCA: prostate stem cell antigen and distinguishing androgen receptor negative prostate cancer from benign prostatic hyperplasia
granted -
US 8758818
Oral tablet compositions of dexlansoprazole
granted -
US 8759284
Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
granted -
US 8758796
Functionalizing implantable devices with a poly (diol citrate) polymer
granted -
US 8758800
Therapeutic implant
granted -
US 8758799
Therapeutic implant
granted -
US 8758798
Therapeutic implant
granted -
US 8759392
Amides as inhibitors of human secreted phospholipase A2
granted -
US 8758723
Compositions and methods for cellular imaging and therapy
granted -
US 8765671
Methods and compositions for modulation of blood-neural barrier
granted -
US 8765171
Methods and compositions for liposomal formulation of antigens and uses thereof
granted -
US 8765168
Compositions of a fluorapatite and methods of use
granted
Frequently asked questions
How many pharma patents expire in 2034?
1,452 published patents in our USPTO index have expiration dates falling in calendar year 2034.